Prostate cancer screening: Statins do not modify mortality risk

Key clinical point: Prostate-specific antigen (PSA)-based prostate cancer screening was associated with less overdiagnosis of low-risk cancer in statin users, with similar risk for advanced disease and mortality compared with nonusers.

Major finding: PSA screening was associated with increased prostate cancer incidence in statin nonusers (rate ratio [RR], 1.31; 95% CI, 1.24-1.38), but not in statin users (RR, 1.02; 95% CI, 0.95-1.10; P for interaction < .001). The screening was not associated with decreased mortality in statin users and nonusers.

Study details: A post hoc analysis of the Finnish Prostate Cancer Screening Trial in which 78,606 men were randomly assigned to either the screening or the control group.

,

Disclosures: This study was supported by Tampere University Hospital, Finnish Cancer Society, and Academy of Finland. The authors received grants, consulting/speaker/personal fees, research funding, compensation, and/or held patents outside this work.

Source: Vettenranta A et al. JAMA Oncol. 2021 Nov 24. doi: 10.1001/jamaoncol.2021.5672.